Conformationally Constrained Tricyclic HIV Integrase Inhibitors

HIV-1 Integrase: Mechanism and Inhibitor Design

Volumn , Issue , 2011, Pages 239-254

  Fardis, Maria ^a   Jin, Haolun ^a   Chen, Xiaowu ^a   Tsiang, Manuel ^a   Chen, James ^a   Kim, Choung ^a   Wright, Matthew ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

IN active site model; SAR of C 5 substituted tricyclic inhibitors; Tricyclic HIV integrase inhibitors

Indexed keywords

EID: 84886173812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118015377.ch16     Document Type: Chapter

References (40)

1. Pommier, Y.; Pilon, A. A.; Bajaj, K.; Mazumder, A.; Neamati, N. HIV-1 integrase as a target for antiviral drugs. Antivir. Chem. Chemother. 1997, 8, 463_483
2. Thomas, M.; Brady, L. HIV integrase: A target for AIDS therapeutics. Trends Biotechnol. 1997, 15, 167_172
3. Pani, A.; Marongiu, M. E. Anti-HIV-1 integrase drugs: How far from the shelf? Curr. Pharm. Des. 2000, 6, 569_584
4. Bukrinsky, M.; Sharova, N.; Stevenson, M. Human immunodeficiency virus type 1 2-LTR circles reside in a nucleoprotein complex which is different from the preintegration complex. J. Virol. 1993, 67, 6863_6865
5. Heinzinger, N. K.; Bukrinsky, M. I.; Haggerty, S. A.; Ragland, A. M.; Kewalramani, V.; Lee, M. A.; Gendelman, H. E.; Ratner, L.; Stevenson, M.; Emerman, M. The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells. Proc. Natl. Acad. Sci. USA 1994, 91, 7311_7315
6. Lee, M. S.; Craigie, R. Protection of retroviral DNA from autointegration: Involvement of a cellular factor. Proc. Natl. Acad. Sci. USA 1994, 91, 9823_9827
7. Kalpana, G. V.; Marmon, S.; Wang, W.; Crabtree, G. R.; Goff, S. P. Science 1994, 266, 2002_2006
8. Farnet, C. M.; Bushman, F. D. HIV-1 cDNA integration: Requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell 1997, 88, 483_492
9. Miller, M. D.; Farnet, C. M.; Bushman, F. D. Human immunodeficiency virus type 1 preintegration complex: Studies of organization and composition. J. Virol., 1997, 71, 5382_5390
10. Chen, H.; Engelman, A. The barrier-to-autointegration protein is a host factor for HIV type 1 integration. Proc. Natl. Acad. Sci. USA 1998, 95, 15270_15274
11. Yung, E.; Sorin, M.; Pal, A.; Craig, E.; Morozov, A.; Delattre, O.; Kappes, J.; Ott, D.; Kalpana, G. V. Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat. Med. 2001, 7, 920_926
12. Cherepanov, P.; Maertens, G.; Proost, P.; Devreese, B.; Van Beeumen, J.; Engelborghs, Y.; De Clercq, E.; Debyser, Z. HIV-1 integrase forms stable tetramers and associates with LEDGF/ p75 protein in human cells. J. Biol. Chem. 2002, 278, 372_381
13. Violot, S.; Hong, S. S.; Rakotobe, D.; Petit, C.; Gay, B.; Moreau, K.; Billaud, G.; Priet, S.; Sire, J.; Schwartz, O.; Mouscadet, J. F.; Boulanger, P. The human polycomb group EED protein interacts with the integrase of human immunodeficiency virus type 1. J. Virol. 2003, 77, 12507_12522
14. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc. Natl. Acad. Sci. USA 1999, 96, 13040_13043
15. Greenwald, J.; Le, V.; Butler, S. L.; Bushman, F. D.; Choe, S. The mobility of an HIV-1 integrase active site loop is correlated with catalytic activity. Biochemistry 1999, 38, 8892_8898
16. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: An active site that binds magnesium. Proc. Natl. Acad. Sci. USA 1998, 95, 9150_9154
17. Maignan, S.; Guilloteau, J. P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: High level of similarity of the active site with other viral integrases. J. Mol. Biol. 1998, 282, 359_368
18. Keseru, G. M.; Kolossvary, I. Fully flexible low-mode docking: Application to induced fit in HIV integrase. J. Am. Chem. Soc. 2001, 123, 12708_12709
19. Dayam, R.; Neamati, N. Active site binding modes of the betadiketoacids: A multi-active site approach in HIV-1 integrase inhibitor design. Bioorg. Med. Chem. 2004, 12, 6371_6381
20. Verschueren, W. G.; Dierynck, I.; Amssoms, K. I. E, Hu, L.; Boonants, P. M. J. G.; Pille, G. M. E. P.; Daeyaert, F. F. D. D.; Hertogs, K.; Surleraux, D. L. N. G.; Wigerinck, P. B. T. P. Design and optimization of tricyclic phtalimide analogues as novel inhibitors of HIV-1 integrase. J. Med. Chem. 2005, 48, 1930_1940
21. Davies, D. R.; Goryshin, I. Y.; Reznikoff, W. S.; Rayment, I. Three-dimensional structure of the Tn5 synaptic complex transposition intermediate. Science 2000, 289, 77_85
22. Wang, J. Y.; Ling, H.; Yang,W.; Craigie, R. Structure of a twodomain fragment of HIV-1 integrase: Implications for domain organization in the intact protein. EMBO J. 2001, 20, 7333_7343
23. Chen, J. C-H.; Krucinski, J.; Miercke, L. J.W.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, A. D.; Stroud, R. M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: A model for viral DNA binding. Proc. Natl. Acad. Sci. USA 2000, 97, 8233_8238
24. Jin, H.; Cai, R. Z.; Schacherer, L.; Jabri, S.; Tsiang, M.; Fardis, M.; Chen, X.; Chen, J. M.; Kim, C. U. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 3989_3992
25. Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J. S.; Zhuang, L.; Fisher, T. E.; Embrey, M.; Guare, Jr., J. P.; Egbertson, M. S.; Vacca, J. P.; Huff, J. R.; Felock, P. J.; Witmer, M. V.; Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M. D.; Espeseth, A. S.; Jin, L.; Chen, I.-W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.;Wong, B. K.; Xu,W.; Pearson, P. G.; Schleif, W. A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 2004, 101, 11233_11238
26. Fardis, M.; Jin, H.; Jabri, S.; Cai, R.; Mish, M.; Tsiang, M.; Kim, C. U. Effect of substitution on novel tricyclic HIV-1 integrase inhibitors. Bioorg. Med. Chem. Lett. 2006, 16, 4031_4035
27. Metobo, S. E.; Jin, H.; Tsiang, M.; Kim, C. U. Design, synthesis, and biological evaluation of novel tricyclic HIVintegrase inhibitors by modification of its pyridine ring. Bioorg. Med. Chem. Lett. 2006, 16, 3985_3988
28. Hansen, J.; Mork, N.; Bundgaard, H. Phenol carbamates of amino acids as prodrug forms for protecting phenols against first-pass metabolism. Int. J. Pharm. 1992, 81, 253_261
29. Jin, H; Wright,M.; Pastor, R.; Mish,M.; Metobo, S.; Jabri, S.; Lansdown, R.; Cai, R.; Pyun, P.; Tsiang, M.; Chen, X.; Kim, C. U. Tricyclic HIV Integrase Inhibitors: Potent and orally bioavailable C5-aza analogs Bioorg. Med. Chem. Lett. 2008, 18, 1388-1391
30. Jones, G. S.; Yu, F.; Zeynalzadegan, A.; Hesselgesser, J.; Chen, X.; Chen, J.; Jin, H.; Kim, C. U.; Wright, M.; Geleziunas, R.; Tsiang, M. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase Antimicrob. Agents Chemother., 2009, 53, 1194_1203
31. Pluymers, W.; Neamati, N.; Pannecouque, C.; Fikkert, V.; Marchand, C.; Burke, Jr., T. R.; Pommier, Y.; Schols, D.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol. Pharmacol. 2000, 58, 641_648
32. Butler, S. L.; Hansen, M. S. T.; Bushman, F. D. A quantitative assay for HIV DNA integration in vivo. Nat. Med. 2001, 7, 631_634
33. Kodama, E.; Shimura, K.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Sato, M.; Kano, M.; Ikeda, S.; Matsuoka, M. In vitro antiviral activity and resistance profile of a novel HIV integrase inhibitor JTK-303/GS-9137. Paper presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27_30, 2006. Abstract Book H-254, p. 276
34. Yoshinaga, T.; Sato, A.; Fujishita, T.; Fujiwara, T. S-1360: In vitro activity of a new HIV-1 integrase inhibitor in clinical development. Paper presented at the 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24_28 2002. Abstract Book 8, p. 55
35. Hazuda, D. J.; Young, S. D.; Guare, J. P.; Anthony, N. J.; Gomez, R. P.; Wai, J. S.; Vacca, J. P.; Handt, L.; Motzel, S. L.; Klein, H. J.; Dornadula, G.; Danovich, R. M.; Witmer, M. V.; Wilson, K. A. A.; Tussey, L.; Schleif,W. A.; Gabryelski, L. S.; Jin, L.; Miller, M. D.; Casimiro, D. R.; Emini, E. A.; Shiver, J. W. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004, 305, 528_532
36. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller,M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000, 287, 646_650
37. Fikkert, V.; Van Maele, B.; Vercammen, J.; Hantson, A.; Van Remoortel, B.; Michiels, M.; Gurnari, C.; Pannecouque, C.; De Maeyer, M.; Engelborghs, Y.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J. Virol. 2003, 77, 11459_11470
38. Fikkert, V.; Hombrouck, A.; Van Remoortel, B.; De Maeyer, M.; Pannecouque, C.; De Clercq, E.; Debyser, Z.; Witvrouw, M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004, 18, 2019_2028
39. King, P. J.; Robinson, Jr., W. E. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J. Virol. 1998, 72, 8420_8424
40. Hare, S.; Gupta, S. S.; Valkov, E.; Engelman, A.; Cherepanov, P. Nature 2001, 464, 232-236.